NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG

NS-089/NCNP-02

The same dose administered in as Part 2 of Study NCNP/DMT02 (40 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).

DRUG

NS-089/NCNP-02

The same dose administered in as Part 2 of Study NCNP/DMT02 (80 mg/kg) will be administered once weekly for 288 weeks (The total treatment period is 312 weeks including Part2 of Study NCNP/DMT02).

Trial Locations (2)

Unknown

Kagoshima University Hospital, Kagoshima

National Center of Neurology and Psychiatry, Tokyo